Latest Breaking News On - Byondis chief medical officer jan schellens - Page 2 : comparemela.com

The FDA has accepted the BLA for [vic-]trastuzumab duocarmazine to treat HER2-positive unresectable locally advanced or metastatic breast cancer.

Jan schellensDrug administrationBiologics license applicationByondis chief medical officer jan schellensPrescription drug user fee act